Vancomycin AUC/MIC Ratio
ورودیهای بالینی بیمار
حداقل ۱۰ — حداکثر ۵۰۰۰ • واحد: mg·h/L
حداقل ۰.۱۲۵ — حداکثر ۸ • واحد: mg/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Below target0–399.9
- In target400–600
- Above target600.1–100000
The Vancomycin AUC/MIC Ratio calculates calculating standardized physiological indices and stratifying general clinical risk. Key inputs include auc24. Scores guide individualizing bedside clinical management, scheduling routine follow-up, and monitoring clinical progress. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Computes the vancomycin AUC24/MIC ratio from a known 24-hour area under the curve and pathogen MIC. Target 400-600 for serious MRSA infections per the 2020 vancomycin consensus guideline.
Clinical Indication
The Vancomycin AUC/MIC Ratio is indicated for bedside clinical practice to support Computes the vancomycin AUC24/MIC ratio from a known 24-hour area under the curve and pathogen MIC. Target 400-600 for serious MRSA infections per the 2020 vancomycin consensus guideline.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult ambulatory and hospitalized patient cohorts evaluated for systemic illness, physiologic risk, or diagnostic probability. Clinical application is indicated across General medical-surgical inpatient units, primary care clinics, and ambulatory outpatient facilities.
Limitations & Contraindications
Single-point score values can obscure rapid temporal clinical deterioration; serial clinical reassessment is essential.
Clinical Pearls & Action Plan
Calculated indices must be contextualized alongside complete clinical history, physical exam, and dynamic trajectory.
AUC/MIC = AUC24 / MIC
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| auc24 | float | Yes | 24-hour area under the curve(mg·h/L) |
| mic | float | Yes | Pathogen MIC(mg/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–399.9 | Below target | AUC/MIC below target |
| 400–600 | In target | AUC/MIC in target |
| 600.1–100000 | Above target | AUC/MIC above target |
Evidence-Based References (EBM)
- Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: a revised consensus guideline. Am J Health-Syst Pharm. 2020;77(11):835-864. (AUC/MIC 400-600)